Table 1.
Demographic and baseline characteristics and laboratory data of drug and placebo groups
| Characteristics | Drug (n=20) | Placebo (n=20) | p-value a | Total (n=40) |
|---|---|---|---|---|
| Male sex [n (%)] | 14 (70) | 11 (55) | 0.327 | 25 (62.5) |
| Age [year, mean±SD] | 6.39±5.04 | 5.85±3.98 | 0.534 | 6.12±4.49 |
| Body surface area [m2, mean±SD] | 0.85±0.37 | 0.8±0.36 | 0.819 | 0.83±0.36 |
| Fars ethnicity | 15 (75) | 14 (70) | 0.668 | 29 (72.5) |
| WBC b [103 cells/µl, mean±SD] | 7.3±4.83 | 10.51±10.12 | 0.561 | 8.9±7.99 |
| ANC b [103 cells/µl, mean±SD] | 0.5±0.5 | 1.08±1.54 | 0.543 | 0.79±1.17 |
| Plt b [103 cells/µl, mean±SD] | 127.7±122.3 | 82.8±97.41 | 0.18 | 105.3±111.5 |
| Hb b [g/dl, mean±SD] | 8.77±2.05 | 8.38±2.16 | 0.499 | 8.58±2.09 |
| AST b [IU/l, mean±SD] | 23.52±36.93 | 46.65±38.51 | 0.014 | 35.09±39.04 |
| ALT b [IU/l, mean±SD] | 43.39±54.52 | 41.9±57.16 | 0.756 | 42.64±55.14 |
| Alk. Pho. b [IU/l, mean±SD] | 304.29±120 | 328.65±125.09 | 0.659 | 316.47±121.6 |
| LDH b [IU/l, mean±SD] | 579.8±411.76 | 1010.15±891.16 | 0.086 | 795±719.01 |
| Positive blood culture c | 2 (10) | 2 (10) | 1 | 4 (10) |
| Positive typhilitis c | 0 | 0 | - | 0 |
| GCSF injection c | 5 (25) | 5 (25) | 1 | 10 (25) |
| Hospitalization time [day, mean±SD] | 23±4.75 | 24.2±7.47 | 0.626 | 23.6±6.21 |
| Compliance [day, mean±SD] | 26.8±4.93 | 26.3±4 | 0.378 | 26.57±4.44 |
a Wilcoxon signed rank test or Chi-square test; b Multiple imputation was used; c recorded during hospital course; Abbreviations: SD: standard deviation, WBC: white blood cell, ANC: absolute neutrophil count, Plt: platelet, Hb: hemoglobin, AST: aspartate transaminase, ALT: alanine transaminase, Alk. Pho.: alkaline phosphatase, LDH: lactate dehydrogenase, GCSF: granulocyte colony stimulating factor